A randomized, single dose, cross-over bioavailability study comparing the drug-drug interaction between telmisartan tablets, indapamide tablets, and amlodipine tablets when co-administered versus the administration of each product alone in three arms to healthy volunteers under fasting conditions.

2024-510835-23-00 Protocol 204-PKT-202301 Human pharmacology (Phase I) - Other Ended

Start 19 Jun 2024 · End 17 Sep 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 204-PKT-202301

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 96
Countries 1
Sites 1

high blood pressure

Key facts

Sponsor
Cepha s.r.o., PRO.MED.CS Praha a.s.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
19 Jun 2024 → 17 Sep 2024
Decision date (initial)
2024-06-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

high blood pressure

VersionLevelCodeTermSystem organ class
24.1 LLT 10005747 Blood pressure high 10047065

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Cepha s.r.o.

Sponsor organisation
Cepha s.r.o.
Address
Komenskeho 19, Severni Predmesti Severni Predmesti
City
Plzen 1
Postcode
323 00
Country
Czechia

Scientific contact point

Organisation
PRO.MED.CS Praha a.s.
Contact name
Jan Sixta

Public contact point

Organisation
PRO.MED.CS Praha a.s.
Contact name
Jan Sixta

PRO.MED.CS Praha a.s.

Sponsor organisation
PRO.MED.CS Praha a.s.
Address
Telcska 377/1, Michle Michle
City
Prague
Postcode
140 00
Country
Czechia

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 96 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Cepha s.r.o.
clinic, Komenskeho 19, Severni Predmesti, Plzen 1

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2024-06-19 2024-09-17 2024-06-19 2024-08-15

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-02 Czechia Acceptable
2024-06-11
2024-06-12